Request Appointment
12902 Usf Magnolia DrTampa, FL 33612
Overview of Dr. Baz
Dr. Rachid Baz is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute, H. Lee Moffitt Cancer Center and Research Institute, and H. Lee Moffitt Cancer Center and Research Institute. He received his medical degree from American University of Beirut Faculty of Medicine and has been in practice 26 years. Dr. Baz accepts several types of health insurance, listed below. He is one of 200 doctors at H. Lee Moffitt Cancer Center and Research Institute and one of 200 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He also speaks multiple languages, including Arabic and French. He has more than 100 publications and over 500 citings.
Education & Training
Cleveland Clinic FoundationFellowship, Hematology and Medical Oncology, 2004 - 2007- Cleveland Clinic FoundationResidency, Internal Medicine, 2001 - 2004
American University of Beirut Faculty of MedicineClass of 2000
Certifications & Licensure
FL State Medical License 2008 - 2028
OH State Medical License 2001 - 2009
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2015-2017
- CMS Meaningful Use Stage 1 Certification PowerChart (CQM), Cerner Corporation, 2015-2017
- CMS Meaningful Use Stage 2 Certification PowerChart (CQM), Cerner Corporation, 2015-2017
Clinical Trials
- Celecoxib in Preventing Multiple Myeloma in Patients With Monoclonal Gammopathy or Smoldering Myeloma Start of enrollment: 2004 Nov 01
- Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM) Start of enrollment: 2008 Jan 01
- Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma Start of enrollment: 2009 Jun 18
Publications & Presentations
PubMed
- Real-world outcomes with elranatamab in multiple myeloma: a multicenter analysis from the U.S. Multiple Myeloma Immunotherapy Consortium.Andrew J Portuguese, James A Davis, Shahzad Raza, Omar Castaneda Puglianini, Ciara Freeman
Blood Cancer Journal. 2026-03-27 - Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: differences by race and ethnicity.Laura B Oswald, Xiaoyin Li, Carina E Ferraris, Gabe De Avila, David Scheiber-Camoretti
Blood Advances. 2026-03-24 - Epigenome-Wide Association Studies of Proteasome Inhibitor-Related Cardiotoxicity in Patients with Multiple Myeloma.Raed Awadh Alshammari, Samuel M Rubinstein, Eric Farber-Eger, Lauren Lee Shaffer, Marwa Tantawy
Cancers. 2026-02-03
Journal Articles
- Twice‐Weekly Ixazomib in Combination with Lenalidomide‐Dexamethasone in Patients with Newly Diagnosed Multiple MyelomaMyo Htut, Michaela Liedtke, Stephen D Smith, Craig C Hofmeister, Rachid Baz, Paul G Richardson, Cara A Rosenbaum, David H Vesole, Ajai Chari, Jesus G Berdeja, Noopur Raje, British Journal of Haematology
Abstracts/Posters
- Panobinostat As a Maintenance Therapy after Autologous Hematopoietic Cell Transplantation for Patients with Multiple MyelomaRachid Baz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- The Result of a Phase 1 Study of Selinexor in Combination with High-Dose Melphalan and Autologous Hematopoietic Cell Transplantation for Multiple MyelomaRachid Baz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Trial in Progress: Phase I Dose-Escalation and Dose-Expansion Trial of a Novel Glutaminase Inhibitor (CB-839 HCl) in Combination with Carfilzomib and Dexamethasone in ...Rachid Baz, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Press Mentions
Year in Review: Multiple MyelomaDecember 2nd, 2024
Moffitt Research of Selinexor for Relapsed/Refractory Multiple Myeloma Facilitates Recent FDA ApprovalJuly 24th, 2019
Plethora of Novel Agents Transforming Outcomes in Multiple MyelomaJuly 28th, 2017
Professional Memberships
- Member
- Member
- Member
Other Languages
- Arabic, French
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPOCoventry Florida - Employer Group PPO
First Health PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
